Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0
|
作者：
Craig Leonardi
Kristian Reich
Peter Foley
Hideshi Torii
Sascha Gerdes
Lyn Guenther
Melinda Gooderham
Laura K. Ferris
Christopher E. M. Griffiths
Hany ElMaraghy
Heidi Crane
Himanshu Patel
Russel Burge
Gaia Gallo
David Shrom
Ann Leung
Chen-Yen Lin
Kim Papp
机构：
[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute
[3] Skinflammation® Center,Division of Dermatology
[4] The University of Melbourne,Psoriasis
[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology
[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital
[7] Guenther Dermatology Research Centre,undefined
[8] SkiN Centre for Dermatology and Probity Medical Research,undefined
[9] University of Pittsburgh Medical Center,undefined
[10] University of Manchester,undefined
[11] Eli Lilly and Company,undefined
[12] Lilly Corporate Center,undefined
[13] Syneos Health,undefined
[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined
来源：
Dermatology and Therapy | 2020年 / 10卷
关键词：
Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 447
页数：16
相关论文
共 50 条
  • [31] The impact of ixekizumab treatment on health-related quality of life in patients with moderate-to-severe psoriasis: results from UNCOVER-1
    Augustin, M.
    Gordon, K.
    Nikai, E.
    Edson-Heredia, E.
    Zhu, B.
    Goldblum, O. M.
    Carlier, H.
    Langley, R. G.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E9 - E9
  • [32] Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: Results from UNCOVER-2
    van de Kerkhof, Peter
    Guenther, Lyn
    Gottlieb, Alice
    Sebastian, Michael
    Wu, Jashin J.
    Foley, Peter
    Morita, Akimichi
    Goldblum, Orin
    Kerr, Lisa
    Rich, Phoebe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [33] Ixekizumab treatment shows a neutral impact on the glucose and lipid profile of patients with moderate-to-severe psoriasis: Results from UNCOVER-1,-2, and-3
    Wu, J. J.
    Egeberg, A.
    Solomon, J. A.
    Osuntokun, O.
    Goldblum, O.
    Moriarty, S.
    Zhao, F.
    Korman, N.
    Vincent, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [34] Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
    Kemeny, Lajos
    Berggren, Lovisa
    Dossenbach, Martin
    Dutronc, Yves
    Paul, Carle
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (01) : 19 - 26
  • [35] Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)
    Leonardi, C. L.
    Langley, R.
    Blauvelt, A.
    Gordon, K.
    Shrom, D. S.
    Farmer-Kerr, L. N.
    Stoykov, I.
    Ojeh, C.
    Reich, K.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E29 - E30
  • [36] Ixekizumab treatment improves skin-related sexual difficulties in patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2 and-3)
    Guenther, L. C.
    Foley, P.
    Cather, J.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    van de Kerkhof, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 79 - 80
  • [37] Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)
    Leonardi, Craig
    Langley, Richard
    Blauvelt, Andrew
    Gordon, Kenneth
    Shrom, David
    Kerr, Lisa
    Stoyko, Ivaylo
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB70 - AB70
  • [38] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 457 - 457
  • [39] Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
    Blauvelt, Andrew
    Lebwohl, Mark G.
    Mabuchi, Tomotaka
    Leung, Ann
    Garrelts, Alyssa
    Crane, Heidi
    ElMaraghy, Hany
    Patel, Himanshu
    Ridenour, Terri
    See, Kyoungah
    Gallo, Gaia
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) : 360 - 368
  • [40] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) (vol 77, pg 855, 2017)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 301 - 301
12345